Back to News
Nov 6, 2025 4:00 PM

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

The deals will also expand Medicare and Medicaid coverage for these high-demand treatments beginning in mid-2026.

In September, Trump announced the first agreement with a major pharmaceutical company, Pfizer Inc. (NYSE:PFE), to bring American drug prices in line with the lowest paid by other developed nations. The iniative is known as the most-favored-nation, or MFN, price.

In October, AstraZeneca Plc (NASDAQ:AZN) inked a new agreement designed to reduce prescription drug costs for Americans.

CNBC reports that the companies will provide their GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, to Medicare and Medicaid for $245 per month.

Medicare patients will pay a $50 copay for approved injectable and oral GLP-1 drugs. This marks the first time the federal program ...